Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Investors Are Buzzing About Threshold Pharmaceuticals, Enbridge, Facebook and More

Page 1 of 2

With the third quarter officially wrapping up at the end of Friday’s close, unexpected volatility in either direction could potentially appear at any time. Volatility certainly reared its head in Asia last night, as the Nikkei 225 fell by over 1.4% and the Hang Seng retreated by more than 1.8%.

In this article, we’ll examine five stocks that are making headlines on Friday, which are Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), Enbridge Inc (USA) (NYSE:ENB), Cempra Inc (NASDAQ:CEMP), Facebook Inc (NASDAQ:FB), and Cisco Systems, Inc. (NASDAQ:CSCO), and see how some of the world’s most successful investors are positioned in them using the latest SEC filing data.

Our research determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor to beat the S&P 500 by around 95 basis points per month (see the details here).
facebook app
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) is down by exactly 50% this morning after the company reported disappointing interim results for its tarloxotinib program. According to CEO Barry Selick, “the overall results from the two studies didn’t meet the activity thresholds required to move forward the molecule forward despite the promising results seen in preclinical translational studies.” Specifically, the investigative drug did not achieve the response rate endpoint in patients with metastatic squamous cell carcinoma of the head and neck, or in patients with advanced EGFR-Mutant, T790M-Negative non-small cell lung cancer. Due to that data, Threshold will make no further investment in the tarloxotinib program and will instead focus on evofosfamide and TH-3424. Of the 749 funds that we track which filed 13Fs for the June quarter, 12 of them had a long position in Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) at the end of the second quarter, up by three from the end of the previous quarter.

Follow Threshold Pharmaceuticals Inc (NASDAQ:THLD)
Trade (NASDAQ:THLD) Now!

Enbridge Inc (USA) (NYSE:ENB) is in the spotlight today after the company announced that it, along with some of its affiliates, has agreed to sell a 994-mile pipeline network in Southeast Saskatchewan to Tundra Energy Market for CAD$1.075 billion, or roughly USD$818 million under current exchange rates. The pipeline transports around 175,000 barrels of crude a day and will get Enbridge about halfway to its non-core asset divestment goal of $2 billion that its management previously set forth in an effort to strengthen its balance sheet after its CAD$37 billion ($28.21 billion) acquisition of Spectra Energy was announced earlier this month. Eric Sprott‘s Sprott Asset Management almost doubled its position in Enbridge Inc (USA) (NYSE:ENB) during the second quarter to just over 600,000 shares at the end of June.

Follow Enbridge Inc (TSE:ENB)
Trade (TSE:ENB) Now!

On the next page, we’ll take a closer look at the latest on Cempra, Facebook, and Cisco Systems.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!